I. To determine whether progression free survival (PFS) is superior after therapy with bendamustine (bendamustine hydrochloride) in combination with rituximab, ibrutinib alone, or ibrutinib in combination with rituximab in patients age 65 or older with previously untreated chronic lymphocytic leukemia (CLL).